Biocytogen leverages genetically engineered proprietary RenMice platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >500,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration.
mAbs with high specificity, affinity and diversity;
Common light chain bsAbs/bsADCs discovery with high pairing success rate and good druggability;
Fully human heavy-chain-only antibodies (HCAbs) or VHHs to penetrate the blood-brain-barrier or infiltrate tumors;
TCR-mimic antibodies with high affinity and specificity to intracellular targets.
Contact us to explore evaluation, licensing, or co-development opportunities!
